Boston Scientific has received CE Mark approval for its Livian cardiac resynchronization therapy defibrillator (CRT-D), which treats heart failure and helps protect patients at risk of sudden cardiac death.

The Livian CRT-D is designed to monitor heartbeats in heart failure patients and deliver small electrical impulses that may improve the heart's pumping ability, according to the Natick, Mass.-based Boston Scientific.

This is the first approval for the company’s cardiac rhythm management device to treat heart failure. The Livian CRT-D is pending approval by the FDA and is not available for sale in the United States.